Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of AZD9793 in advanced hepatocellular carcinoma (RHEA-1)
jRCT2031250484Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of AZD9793 in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Primary endpoints: Safety - adverse events, Safety - serious adverse events and 4 more. Started Dec 2025; status: recruiting.
02
Drugs
AZD9793
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031250484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250484.